Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab plus Olomorasib in metastatic KRAS G12C-mutated NSCLC
CTR20254925Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab, olomorasib in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Mar 2026; status: active.
02
Drugs
amivantamabolomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20254925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254925.